Avendus Capital Advises the Promoters of J.B. Chemicals & Pharmaceuticals on the Sale of a Controlling Stake to KKR

For more than four decades, J.B. Chemicals’ mission has been to deliver affordable, high-quality pharmaceutical products that improve the lives of individuals living in India and around the world. We are thrilled that KKR – with its deep knowledge of the pharmaceutical industry and experience in investing in the sector, as well as its extensive investments in India – will take our mission forward and build on the foundation of core values that our family has instilled in this company. This will also create growth opportunities for our people to progress.

We are pleased that the promoters of J.B. Chemicals have selected us to take over their rich legacy and to help the company continue its expansion, which is clearly driven by its diversified product portfolio and state-of-the-art manufacturing capabilities. We believe J.B. Chemicals has an opportunity to accelerate its growth and leverage its strengths to enter new therapeutic areas. We look forward to working with the management team to build on the company’s strong foundation and believe this investment underscores KKR’s ongoing commitment to India’s long-term economic prospects and the potential of its companies.

We are delighted to partner with the Mody family and help them transition a 40 plus-year legacy to a global blue-chip investor like KKR. The transition comes at a time when the pharmaceuticals ecosystem is rapidly evolving, seeing significant competitive and regulatory shifts across segments and markets.